David A. Siegel Larimar Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 252,371 shares of LRMR stock, worth $853,013. This represents 0.0% of its overall portfolio holdings.

Number of Shares

252,371

Previous 1,146,924 78.0%

Holding current value

$853,013

Previous $3.31 Million 75.41%

% of portfolio

0.0%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$2.88 - $5.1 $2.58 Million - $4.56 Million	-894,553 Reduced 78.0%	252,371 $815,000
Q2 2025 Aug 14, 2025	BUY	$1.71 - $3.25 $1.29 Million - $2.45 Million	752,900 Added 191.08%	1,146,924 $3.31 Million
Q1 2025 May 15, 2025	BUY	$2.15 - $4.18 $703,050 - $1.37 Million	327,000 Added 487.88%	394,024 $847,000
Q4 2024 Feb 14, 2025	SELL	$3.8 - $9.29 $114,380 - $279,629	-30,100 Reduced 30.99%	67,024 $256,000
Q3 2024 Nov 14, 2024	SELL	$6.3 - $10.68 $220,500 - $373,800	-35,000 Reduced 26.49%	97,124 $636,000

Q2 2024 Aug 14, 2024	SELL	$6.33 - $9.89 $388,029 - $606,257	-61,300 Reduced 31.69%	132,124 $957,000
Q1 2024 May 15, 2024	BUY	$4.2 - $13.28 $353,220 - $1.12 Million	84,100 Added 76.93%	193,424 $1.47 Million
Q4 2023 Feb 14, 2024	SELL	$2.35 - $4.71 $117,265 - $235,029	-49,900 Reduced 31.34%	109,324 $497,000
Q3 2023 Nov 14, 2023	SELL	$3.08 - $4.49 $195,580 - $285,115	-63,500 Reduced 28.51%	159,224 $628,000
Q2 2023 Aug 14, 2023	SELL	$3.13 - $5.27 $69,799 - $117,520	-22,300 Reduced 9.1%	222,724 $697,000
Q1 2023 May 15, 2023	BUY	$4.0 - $6.68 $442,000 - $738,140	110,500 Added 82.14%	245,024 $1.11 Million
Q4 2022 Feb 14, 2023	BUY	$2.73 - $5.08 $163,254 - $303,784	59,800 Added 80.03%	134,524 $555,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.64 $114,327 - $271,995	74,724 New	74,724 $239,000
Q2 2022 Aug 15, 2022	SELL	$1.9 - $3.98 $26,596 - $55,712	-13,998 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.65 - $10.84 $51,830 - $153,928	-14,200 Reduced 50.36%	13,998 $57,000
Q4 2021 Feb 14, 2022	SELL	$8.86 - $13.47 $41,642 - $63,309	-4,700 Reduced 14.29%	28,198 $304,000
Q3 2021 Nov 15, 2021	BUY	$9.61 - $15.11 $316,149 - $497,088	32,898 New	32,898 $379,000
Q2 2021 Aug 16, 2021	SELL	$8.0 - $15.2 $93,512 - $177,672	-11,689 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$14.61 - $22.19 $27,759 - $42,161	1,900 Added 19.41%	11,689 $171,000
Q4 2020 Feb 16, 2021	BUY	$14.28 - $25.06 $139,786 - $245,312	9,789 New	9,789 $210,000
Q3 2020 Nov 16, 2020	SELL	$10.5 - $17.6 $141,708 - $237,529	-13,496 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$0.72 - $16.76 $9,717 - $226,192	13,496 New	13,496 $173,000

Others Institutions Holding LRMR

# of Institutions

155

Shares Held

89M

Call Options Held

6.44M

Put Options Held

622K

View Full List

About Larimar Therapeutics, Inc.

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $146M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

More about LRMR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account